Novo Nordisk beats on Wegovy sales, expects slower 2025 growth
Novo's earnings results Wednesday differ from Eli Lilly's, whose stock slid on slower-than-expected sales of weight loss ...
BioSpace51m
Despite Doubled Wegovy Sales, Novo Executives Confront Analysts’ Insatiable Appetite
Wegovy sales increased by more than 100% over 2024. But that wasn’t enough to satiate analysts who want to know why Novo Nordisk can’t access more patients, particularly in the U.S.
Hosted on MSN30m
Novo Nordisk Stock Jumps On Q4 Beat: Retail Brushes Off Slower Growth Outlook To Chase Obesity Drug Boom
NYSE-listed shares of Novo Nordisk surged 4% on Wednesday morning after the Danish pharmaceutical giant posted ...
Hosted on MSN37m
Novo Surges As Ozempic Drives Fourth-Quarter Beat. But Supply Shortages Expected.
Novo Nordisk stock reversed a three-day downtrend Wednesday after the weight-loss drugs kingpin leaned on Ozempic for a ...